Risk Of Developing Liver Cancer After HCV Treatment

Monday, March 27, 2017

MSF joins Europe-wide action challenging patent on key hepatitis C drug

MSF joins Europe-wide action challenging patent on key hepatitis C drug

Patent opposition aims to increase affordable access to hepatitis C drug sofosbuvir for millions

No comments:

Post a Comment